The 2018 Nobel Prize in Medicine was awarded to a team that discovered PD-1 inhibitors; drugs that harness the power of a patient’s own immune system to recognize and fight cancer. While these drugs lead to blockbuster responses in around 10-20% of patients with most cancer types, a large majority of patients do not get significant benefit. We plan to change that. Thanks to contributions through The Rare Initiative, Dr Lipika Goyal and her team will partner with our pathologists to perform immunoprofiles on individual patient tumors. These profiles will help develop personalized immunotherapy treatment plans, giving new options to more cancer patients with RARE cancers.